INAF Stock Overview
Manufactures and sells pharmaceutical products in Indonesia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PT Indofarma Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp126.00 |
| 52 Week High | Rp725.00 |
| 52 Week Low | Rp126.00 |
| Beta | -0.049 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -74.29% |
| 33 Year Change | -94.50% |
| 5 Year Change | -90.74% |
| Change since IPO | -38.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| INAF | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -2.2% |
| 1Y | -74.3% | -9.4% | 9.3% |
Return vs Industry: INAF underperformed the ID Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: INAF underperformed the ID Market which returned 14.4% over the past year.
Price Volatility
| INAF volatility | |
|---|---|
| INAF Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in ID Market | 12.6% |
| 10% least volatile stocks in ID Market | 2.4% |
Stable Share Price: INAF has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine INAF's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1918 | 900 | . Yeliandriani | indofarma.id |
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutical, and medical equipment; and engages in herb infusion, health support, private polyclinic, general practitioner, dentist, and internet trading applications activities.
PT Indofarma Tbk Fundamentals Summary
| INAF fundamental statistics | |
|---|---|
| Market cap | Rp390.51b |
| Earnings (TTM) | -Rp702.59b |
| Revenue (TTM) | Rp269.35b |
1.4x
P/S Ratio-0.6x
P/E RatioIs INAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INAF income statement (TTM) | |
|---|---|
| Revenue | Rp269.35b |
| Cost of Revenue | Rp445.42b |
| Gross Profit | -Rp176.06b |
| Other Expenses | Rp526.52b |
| Earnings | -Rp702.59b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -226.69 |
| Gross Margin | -65.37% |
| Net Profit Margin | -260.84% |
| Debt/Equity Ratio | -81.2% |
How did INAF perform over the long term?
See historical performance and comparison